Kc Tse
University of Hong Kong
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Kc Tse.
Lupus | 2005
Kc Tse; Fu Keung Li; Scw Tang; C. S.-O. Tang; K.N. Lai; Tm Chan
Angiotensin-converting enzyme inhibitor (ACEI) or angiotensin II receptor blocker (ARB) reduces proteinuria and the rate of renal function deterioration in diabetic nephropathy and other glomerular diseases, but its role in quiescent lupus nephritis has not been established. We conducted a retrospective study to investigate the effects of ACEI/ARB on proteinuria and renal function in patients with persistent proteinuria (>1 g/day) despite resolution of acute lupus nephritis following immunosuppressive treatment. Fourteen out of 92 patients were included. The duration of treatment with ACEI/ARB was 52.1 ± 35.7 months. The levels of proteinuria, serum albumin, serum creatinine, systolic and diastolic blood pressure were 1.10 to 6.90 g/day, 35.8 ± 3.6 g/L, 102.54 ± 34.48 μmol/L, 137.6 ± 10.9 and 81.9 ± 9.2 mmHg at baseline. Proteinuria and serum albumin showed significant sustained improvements after 6 and 24 months of treatment. Comparison of slopes for serial proteinuria, albumin and reciprocal of serum creatinine before and after treatment showed significant improvements in six (43%), eight (57%) and two patients, respectively. At last follow-up proteinuria remained significantly lower (0.36 g/day, P = 0.043) and albumin higher (41.3 ± 2.2 g/L, P = 0.023). Eleven (78.6%) patients had proteinuria improved by >50%, and five had insignificant proteinuria at last follow-up. Systolic blood pressure was significantly reduced from 6 months onwards, but this did not correlate with proteinuria reduction. Diastolic blood pressure, serum creatinine, creatinine clearance, anti-dsDNA, C3 and haemoglobin were not altered. We conclude that ACEI/ARB effectively reduces proteinuria and improves serum albumin in patients with persistent proteinuria despite quiescent lupus nephritis.
Lupus | 2006
Kc Tse; C. S.-O. Tang; W. I. Lio; M. F. Lam; Tm Chan
There is accumulating evidence that mycophenolate mofetil (MMF), when combined with corticosteroid, is an effective induction treatment for severe proliferative lupus nephritis and is associated with fewer adverse effects compared to cyclophosphamide (CTX), but the quality of life (QOL) associated with these regimens as perceived by the patient has not been compared. This study included patients who had experienced both treatment regimens, for distinct episodes of diffuse proliferative lupus nephritis. QOL parameters during the first six months of each treatment were assessed through SF36 and WHOQOL questionnaires. Twelve patients and 24 episodes of severe lupus nephritis were studied. CTX-treated and MMF-treated episodes showed comparable baseline characteristics and response rate, with complete remission occurring in 83.3%. MMF treatment was associated with higher numerical scores for all domains across both QOL instruments than CTX. MMF treatment was associated with significantly less fatigue, less impediment of physical and social functioning, and better psychological well being compared to CTX. When each patient served as her/his own control, most patients ascribed higher QOL domain scores to the MMF-treated episode. Seventy-five percent of patients found MMF treatment more acceptable and preferred when compared with CTX, and the complications that most concerned them included Cushingoid features, alopecia, menstrual disturbance and infections. These data showed that MMF-based induction immunosuppression for severe lupus nephritis was associated with better QOL than CTX as perceived by patients, which was most likely attributed to the reduced side-effects during MMF treatment.
Clinical and Experimental Immunology | 2004
K.N. Lai; Jck Leung; Lyy Chan; Fk Li; Scw Tang; M. F. Lam; Kc Tse; Terence Pok-Siu Yip; Tm Chan; A. Wieslander; H. Vlassara
Autoclaving peritoneal dialysate fluid (PDF) degrades glucose into glucose degradation products (GDPs) that impair peritoneal mesothelial cell functions. While glycation processes leading to formation of advanced glycation end‐products (AGE) were viewed commonly as being mediated by glucose present in the PDF, recent evidence indicates that certain GDPs are even more powerful inducers of AGE formation than glucose per se. In the present study, we examined the expression and modulation of AGE receptors on human peritoneal mesothelial cells (HPMC) cultured with GDPs, conventional PDF or PDF with low GDP content. HPMC cultured with GDPs differentially modulated AGE receptors (including RAGE, AGE–R1, AGE–R2 and AGE–R3) expression in a dose‐dependent manner. At subtoxic concentrations, GDPs increased RAGE mRNA expression in HPMC. 2‐furaldehyde (FurA), methylglyoxal (M‐Glx) and 3,4‐dideoxy‐glucosone‐3‐Ene (3,4‐DGE) increased the expression of AGE–R1 and RAGE, the receptors that are associated with toxic effects. These three GDPs up‐regulated the AGE synthesis by cultured HPMC. In parallel, these GDPs also increased the expression of vascular endothelial growth factor (VEGF) in HPMC. PDF with lower GDP content exerted less cytotoxic effect than traditional heat‐sterilized PDF. Both PDF preparations up‐regulated the protein expression of RAGE and VEGF. However, the up‐regulation of VEGF in HPMC following 24‐h culture with conventional PDF was higher than values from HPMC cultured with PDF containing low GDP. We have demonstrated, for the first time, that in addition to RAGE, other AGE receptors including AGE–R1, AGE–R2 and AGE–R3 are expressed on HPMC. Different GDPs exert differential regulation on the expression of these receptors on HPMC. The interactions between GDPs and AGE receptors may bear biological relevance to the intraperitoneal homeostasis and membrane integrity.
Internal Medicine Journal | 2003
Kc Tse; P-S. Yip; M. F. Lam; Choy; Fk Li; Sl Lui; Wk Lo; Tm Chan; K.N. Lai
Abstract
Transplant Infectious Disease | 2008
Kc Tse; Scw Tang; Tm Chan; K.N. Lai
Abstract: In this report, a renal transplant recipient with Rhodococcus lung abscess is described. A high clinical suspicion and appropriate combination antibiotic therapy obviated the need for surgical intervention and was associated with a good clinical outcome. The optimal regimen of combination antibiotic therapy is discussed.
Lupus | 2002
Sl Lui; M. F. Lam; Kc Tse; Wk Lo
The disease activity of patients suffering from lupus nephritis usually becomes quiescent after the onset of end stage renal failure. Reactivation of lupus activity, especially after a long period of dialysis, is uncommon. Factors that might trigger off lupus reactivation after dialysis have not been well defined. We report a case of a 43-year-old Chinese woman on long-term peritoneal dialysis, who developed lupus reactivation with cerebral involvement 2 weeks after she was diagnosed to have tuberculous peritonitis. The close temporal relationship between the tuberculous peritonitis and the lupus reactivation raise the possibility that the tuberculous infection might have triggered off the lupus reactivation.
Archive | 2010
Dyh Yap; Cso Tang; Mkm Ma; Kc Tse; Mf Lam; Tm Chan
Introduction: Angiotensin II (AT II) plays a important role in the development of proteinuria not only by hemodynamic but also pathologic effects. As the podocyte is a main component in glomerular fi ltration units, we investigated the effect of AT II on the quantitative and qualitative changes of podocyte cytoskeletal proteins. Methods: Cultured podocytes were treated with various concentrations of AT II and losartan, a AT II type 1 receptor blocker. The quantitative changes of podocyte cytoskeletal proteins including α-actinin, synaptopodin, and I-plastin were analyzed by Western blotting (WB) and RT-PCR and the qualitative distributional changes were observed by confocal microscopy. Results: AT II decreased the amount of these three cytoskeletal proteins in WB signifi cantly in a dose-dependent manner, which were reversed by losartan. However, mRNA expressions of cytoskeletal proteins by RT-PCR were unremarkable. In confocal imaging, these three cytoskeletal proteins were co-localized. AT II changed the distribution of α-actinin from peripheral to inner cytoplasm and those of synaptopodin and I-plastin into concentrated in dosedependent manner, which were also attenuated by losartan. Conclusion: AT II modulates the phenotypes of podocyte cytoskeletal proteins via AT II type 1 receptor, therefore, may induce pathologic changes of podocytes, resulting proteinuria. *This research work was supported by the organizing committee of APCN2010.
Archive | 2006
Scw Tang; Ssy Yung; Cso Tang; Mf Lam; Rcw Tsang; Kc Tse; Kn Lai; Yw Ho; Mkl Tong; Dtm Chan
Archive | 2010
Dyh Yap; Cso Tang; Mkm Ma; Kc Tse; Mf Lam; Dtm Chan
Archive | 2010
T Yip; Kc Tse; Mf Lam; Swk Cheng; Sl Lui; Scw Tang; Mmt Ng; Dtm Chan; Kn Lai; Wk Lo